JBIO
HealthcareJade Biosciences, Inc. · Biotechnology · $730M
What is Jade Biosciences, Inc.?
Jade Biosciences is an early-stage biotechnology company focused on developing therapies for autoimmune diseases. Founded in 2025 and headquartered in Waltham, Massachusetts, the company is building a pipeline centered on IgA nephropathy and related conditions.
Jade Biosciences targets the APRIL pathway — a mechanism implicated in certain autoimmune diseases — with its lead drug candidate, JADE-001, aimed at treating IgA nephropathy. The company generates no commercial revenue at this stage; it is advancing its pipeline through preclinical and early clinical development. Two additional antibody programs, JADE-002 and JADE-003, round out its early-stage research portfolio.
Jade Biosciences was founded in 2025 and is headquartered in Waltham, US.
- JADE-001 — lead clinical candidate targeting the APRIL pathway for IgA nephropathy
- JADE-002 — preclinical antibody program
- JADE-003 — preclinical antibody program
- Autoimmune disease research platform
Is JBIO a Good Stock to Buy?
UQS Score rates JBIO as Poor overall, reflecting the realities of a pre-revenue biotech at the earliest stages of clinical development.
The Risk pillar stands out as the relative bright spot within JBIO's profile — a notable distinction for a company this early in its lifecycle. This may reflect a conservative balance-sheet posture typical of recently formed biotechs.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no approved products and limited operating history. Valuation is rated Elevated, meaning the current price already embeds significant expectations.
See the complete pillar-by-pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does JBIO pay dividends?
Yes — Jade Biosciences, Inc. pays a dividend.
Despite its early-stage status, JBIO is listed as paying a regular dividend — an unusual characteristic for a pre-revenue biotech. Investors should verify the current dividend status and any associated terms directly through the company's investor relations disclosures, as policies at early-stage companies can change rapidly.
When does JBIO report earnings?
Jade Biosciences reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue company, quarterly reports focus primarily on cash runway, research and development expenditures, and pipeline milestones rather than traditional revenue or earnings metrics. Progress on JADE-001's anticipated clinical trial entry is the key operational update to watch.
For the most recent quarter's results and pipeline updates, visit Jade Biosciences' investor relations page.
JBIO Price History
-95.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Jade Biosciences, Inc.?
Based on Jade Biosciences, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
JBIO Long-term Outlook
JBIO's Growth pillar is rated Weak, which reflects the absence of commercial products and the long runway before any potential approval. The path forward depends almost entirely on clinical execution — particularly JADE-001's trial initiation and early data readouts. The Elevated Valuation rating suggests the market has already priced in optimistic scenarios, leaving limited margin for setbacks.
Growth drivers
- JADE-001 clinical trial initiation and early efficacy data in IgA nephropathy
- Potential pipeline expansion through JADE-002 and JADE-003 preclinical programs
- Growing unmet need in autoimmune disease treatment
Key risks
- Clinical trial failure or delays for JADE-001
- Elevated valuation relative to the company's pre-revenue stage
- Dependence on external financing to fund ongoing research and development
JBIO vs Peers
JBIO operates in a competitive early-stage biotech landscape alongside several small-cap peers pursuing similar or adjacent therapeutic areas.
BridgeBio Oncology focuses on oncology rather than autoimmune disease, giving it a distinct therapeutic focus from JBIO's APRIL-pathway approach.
SELLAS pursues cancer immunotherapy with a more advanced clinical-stage pipeline, distinguishing it from JBIO's earlier development timeline.
Gyre Therapeutics targets fibrotic and inflammatory diseases, overlapping thematically with autoimmune conditions but through a different mechanistic lens.
Frequently Asked Questions
What does Jade Biosciences do?
Jade Biosciences is a biotechnology company developing therapies for autoimmune diseases. Its lead program, JADE-001, targets the APRIL pathway to treat IgA nephropathy. The company also has two earlier-stage antibody programs, JADE-002 and JADE-003, in preclinical development.
Does JBIO pay dividends?
JBIO is listed as paying a regular dividend, which is uncommon for a pre-revenue biotech. Investors should confirm the current dividend policy and any conditions directly with the company's investor relations team, as early-stage companies can alter these arrangements quickly.
When does JBIO report earnings?
Jade Biosciences reports on a quarterly cadence typical of US-listed public companies. Because the company is pre-revenue, reports center on pipeline progress and cash position rather than traditional earnings. Check the company's investor relations page for the latest schedule.
Is JBIO a good stock to buy?
UQS Score rates JBIO as Poor overall. Quality, Moat, and Growth are all rated Weak, while Valuation is Elevated — meaning expectations embedded in the price are already high. The Risk pillar is the relative standout. This profile is typical of early-stage biotechs with unproven pipelines.
Is JBIO overvalued?
The UQS Valuation pillar for JBIO is rated Elevated, suggesting the current market price reflects optimistic assumptions about clinical success. For a company with no approved products and no commercial revenue, this leaves limited room for pipeline disappointments.
How does JBIO compare to its competitors?
Compared to peers like SELLAS Life Sciences and Gyre Therapeutics, JBIO is at an earlier stage of development with a narrower pipeline. Its focus on the APRIL pathway for IgA nephropathy is a differentiated approach, but it carries the higher execution risk typical of pre-clinical-stage assets.
What is JBIO's market cap bracket?
JBIO is classified as a small-cap stock. This places it among smaller publicly traded companies, where liquidity can be lower and price volatility tends to be higher than in large- or mega-cap names.
Who founded Jade Biosciences?
Jade Biosciences was founded in 2025. Specific founding team information is publicly available through the company's official disclosures and investor relations materials, which are the most reliable source for leadership details.
Is JBIO a long-term quality investment?
As a long-term quality indicator, UQS rates JBIO as Poor. The Weak scores across Quality, Moat, and Growth reflect the absence of durable competitive advantages and commercial traction at this stage. Long-term quality typically improves as clinical milestones are achieved and a moat begins to form.
What is the main competitive advantage of Jade Biosciences?
Jade Biosciences is pursuing a targeted approach to the APRIL pathway, which the company believes can deliver best-in-class outcomes in IgA nephropathy. However, the UQS Moat pillar is currently rated Weak, reflecting that no durable competitive advantage has yet been established.
Unlock Full JBIO Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar scores for JBIO
- ✓Access detailed financial metrics and trend data
- ✓Compare JBIO side-by-side with biotech peers
- ✓Track pipeline milestones and their quality implications
- ✓Get the complete analyst-grade view available to Pro members
Pro Analysis
JBIO — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Jun 14, 2026 | 16.6 | 0.0 | 9.0 | 18.5 | 71.3 | 0.0 | -0.1 |
| May 20, 2026 | 16.7 | 0.0 | 9.0 | 18.5 | 71.4 | 0.0 | +0.8 |
| Apr 22, 2026 | 15.9 | 0.0 | 9.0 | 18.5 | 66.5 | 0.0 | -0.9 |
| Apr 10, 2026 | 16.8 | 0.0 | 9.0 | 23.1 | 66.5 | 0.0 | — |
JBIO — Pillar Breakdown
Quality
— 0.0/100 (25%)Jade Biosciences, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 18.5/100 (20%)Jade Biosciences, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 71.3/100 (15%)Jade Biosciences, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Jade Biosciences, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 9/100 (25%)Jade Biosciences, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for JBIO.
Score Composition
Financial Data
More Stock Analysis
How is the JBIO UQS Score Calculated?
The UQS (Unified Quality Score) for Jade Biosciences, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Jade Biosciences, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Jade Biosciences, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.